NEW YORK — Wall Street opened the final trading session of the week with a sharply divided group of winners and losers as investors reacted to fresh analyst downgrades, weaker corporate earnings guidance, clinical-trial developments and a renewed surge in cryptocurrency prices.
Among the stocks drawing the most attention were Netflix (NFLX), Nucor (NUE), Steel Dynamics (STLD) and Xenon Pharmaceuticals (XENE), all of which came under pressure in premarket trading. At the same time, several cryptocurrency-linked stocks moved sharply higher as Bitcoin climbed back above the $78,000 level.
The moves came against a complicated backdrop for U.S. markets. Treasury yields remained elevated, oil prices were still above $100 a barrel, and investors were digesting the Federal Reserve’s recent interest-rate decision and its implications for inflation and economic growth.
Netflix tumbles after Wells Fargo downgrade
Netflix was one of the most closely watched decliners.
Shares fell more than 3% in premarket trading after Wells Fargo downgraded Netflix to Underweight from Equal Weight and reduced its price target from $80 to $57.
The bank cited concerns about user engagement and Netflix’s upcoming content slate. Analyst Steven Cahall’s team said engagement trends appeared concerning and argued that Netflix has lacked the kind of major original programming that previously generated significant momentum for the platform.
The pressure continued during regular trading. Netflix ultimately finished September 18 at about $71.79, down 4.67%.
The downgrade highlights an important issue for the streaming giant: Netflix is increasingly expanding beyond traditional scripted television and movies into areas including gaming, documentaries, reality programming and video podcasts, but analysts are questioning whether the company can continue generating the blockbuster shows needed to sustain engagement.
Wells Fargo’s assessment was particularly focused on future content performance rather than a single quarterly result.
Nucor and Steel Dynamics hit by weaker earnings outlooks
The steel sector also came under pressure.
Nucor, one of America’s largest steel producers, fell after forecasting third-quarter adjusted earnings below Wall Street expectations.
The company projected third-quarter earnings of approximately $5.55 to $5.65 per share, below analysts’ expectations. Nucor said it expected stronger performance from its steel mills and steel-products businesses, but weaker results from its raw-materials segment were expected to weigh on overall earnings.
Steel Dynamics faced a similar reaction after issuing third-quarter guidance that also disappointed analysts.
Both companies nevertheless projected substantially higher earnings than they recorded a year earlier. The problem for investors was that the forecasts did not clear market expectations.
By the end of Friday’s session, Nucor had fallen roughly 6.1%, while Steel Dynamics declined about 4.6%, according to market reports.
The episode illustrates a recurring feature of financial markets: even when a company’s projected earnings are improving significantly year over year, its stock can fall if the outlook fails to meet expectations already built into the share price.
Xenon Pharmaceuticals suffers the biggest blow
Among the major premarket decliners, Xenon Pharmaceuticals delivered one of the most dramatic moves.
The biotechnology company temporarily paused new patient enrollment in ongoing clinical studies involving azetukalner, an experimental treatment being evaluated for psychiatric conditions including major depressive disorder and bipolar depression.
The company said the decision followed reports of neuropsychiatric adverse events. At the same time, Xenon announced that it had submitted a New Drug Application to the U.S. Food and Drug Administration for azetukalner as a potential treatment for focal seizures associated with epilepsy.
Xenon’s shares plunged roughly 26% in premarket trading and ultimately closed down about 30.7%.
The development also triggered a response from Deutsche Bank, which downgraded Xenon from Buy to Hold. Analysts said the clinical update affected their assessment of azetukalner’s potential in the epilepsy market.
For investors, the situation is particularly significant because biotechnology valuations can be heavily influenced by clinical-trial results and regulatory milestones. A change in the perceived risk profile of a lead drug candidate can therefore produce much larger stock moves than ordinary earnings news.
Bitcoin-linked stocks move in the opposite direction
While Netflix, steelmakers and Xenon were falling, another corner of the market was moving sharply higher.
Bitcoin climbed back above $78,000 during Friday’s trading, helping lift companies with significant exposure to the cryptocurrency market.
Coinbase, Strategy and Robinhood were among the major beneficiaries. Reuters reported that the three companies gained between approximately 9.1% and 16.4% during Friday’s session as Bitcoin jumped about 5.9%.
Market reports also noted strong gains among other crypto-related companies.
The move demonstrated how quickly capital was rotating between different areas of the market as investors responded to changes in cryptocurrency prices, interest-rate expectations and broader risk appetite.
On Holding gets a boost from Kylian Mbappé deal
Not every closely watched stock was falling.
On Holding attracted attention after announcing a partnership with soccer superstar Kylian Mbappé to develop football products and represent the Swiss sportswear brand.
The agreement gives On a high-profile entry point into the global football market and places the company in more direct competition with established sportswear giants such as Nike and Adidas.
The news initially pushed On Holding shares higher in premarket trading, although the stock ultimately finished the regular session slightly lower.
AI stocks provide another pocket of strength
The market’s gains were not limited to cryptocurrency-linked companies.
Several semiconductor and AI-related stocks also attracted buying interest, with Intel, Lam Research, Applied Materials and KLA among the technology names posting gains during Friday’s session.
Intel rose in premarket trading as investors continued to favor parts of the semiconductor complex despite broader uncertainty surrounding rates and the economy.
That helped support the Nasdaq even as weakness in other sectors limited broader market gains.
A volatile week ends with mixed results
Friday’s trading session capped a turbulent week for U.S. markets.
Reuters reported that the S&P 500 finished the week nearly flat, while the Nasdaq ended higher, helped by semiconductor stocks. The Dow Jones Industrial Average, however, suffered its largest weekly percentage decline since March.
The market was also dealing with unusually high Treasury yields, with benchmark yields moving above 5%, while oil remained above $100 a barrel. Those conditions have kept inflation and interest rates at the center of investors’ calculations.
Market breadth also remained weak. On the New York Stock Exchange, declining issues outnumbered advancing stocks by roughly 1.78 to 1, while Nasdaq decliners also outnumbered gainers.
The bigger story behind Friday’s stock moves
Taken together, Friday’s biggest stock moves reveal a market being driven by company-specific catalysts as much as by broad economic trends.
Netflix faced questions over content and engagement. Nucor and Steel Dynamics were punished for guidance that fell short of expectations. Xenon was hit by a clinical-trial setback. Meanwhile, cryptocurrency stocks benefited from Bitcoin’s renewed climb, while semiconductor companies continued to attract interest from investors focused on artificial intelligence.
The contrast is striking.
A single trading session produced major declines in streaming, steel and biotechnology alongside powerful gains in cryptocurrency and selected technology stocks.
And with Treasury yields, oil prices, inflation and Federal Reserve policy still influencing valuations, Wall Street enters the next week with investors watching one question closely:
Are these moves isolated reactions to individual corporate developments—or signs that money is beginning to rotate more aggressively between the market’s biggest themes?
